The 11-member committee voted nearly unanimously in November that Biogen’s drug should not be approved. The FDA approved it anyway.

Two members of the U.S. Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory Committee resigned after the agency’s approved the controversial Alzheimer’s drug aducanumab (Aduhelm, Biogen/Eisai), against the committee’s recommendation. The 11-member committee voted nearly unanimously in November that Biogen’s drug should not be approved. The FDA approved it anyway. Price forContinue reading “The 11-member committee voted nearly unanimously in November that Biogen’s drug should not be approved. The FDA approved it anyway.”